Portola Valley, CA, United States

Bayhill Therapeutics

bayhilltx.com
Portola Valley, CA, United States
SEARCH FILTERS
Time filter
Source Type

The Biological Therapeutics Research and Development-GTCbio's Fifth Annual Conference, held in San Francisco, included topics covering new therapeutic developments in the field of vaccines and peptide therapies. This conference report highlights selected presentations on the development of vaccines for NSCLC, DNA delivery platforms as vaccines, vaccine combination therapy for cancer, DNA vaccines for autoimmune diseases, and improved peptide therapeutics. Investigational drugs discussed include TG-4010 (Transgene), and a series of vaccines targeting autoimmune diseases, including BHT-3021 (Bayhill/Genentech) for type I diabetes, BHT-3009 (Bayhill) for multiple sclerosis and BHT-3034 (Bayhill) for myasthenia gravis. © Thomson Reuters (Scientific) Ltd.


The Gene Based Vaccines: Optimising Development and Delivery conference, held in Vienna, included topics covering new therapeutic developments in the field of gene-based vaccines. This conference report highlights selected presentations on gene-based vaccine delivery systems, anti-vector immunity in such vaccines, gene-based influenza vaccines, prime-boost strategies for influenza vaccines, DNA vaccines for the prevention of malaria, considerations in DNA vaccine manufacturing, and the ImmunoBody DNA vaccine technology from Scancell. © Thomson Reuters (Scientific) Ltd.


Fontoura P.,Hoffmann-La Roche | Fontoura P.,New University of Lisbon | Garren H.,Bayhill Therapeutics
Results and Problems in Cell Differentiation | Year: 2010

The current treatments for multiple sclerosis (MS) are, by many measures, not satisfactory. The original interferon-β therapies were not necessarily based on an extensive knowledge of the pathophysiological mechanisms of the disease. As more and more insight has been acquired about the autoimmune mechanisms of MS and, in particular, the molecular targets involved, several treatment approaches have emerged. In this chapter, we highlight both promising preclinical approaches and therapies in late stage clinical trials that have been developed as a result of the improved understanding of the molecular pathophysiology of MS. These clinical stage therapies include oral agents, monoclonal antibodies, and antigen-specific therapies. Particular emphasis is given to the molecular targets when known and any safety concerns that have arisen because, despite the need for improved efficacy, MS remains a disease in which the safety of any agent remains of paramount importance. © 2010 Springer-Verlag Berlin Heidelberg.


Patent
Bayhill Therapeutics and Stanford University | Date: 2011-03-23

This invention relates to methods and compositions for treating or preventing disease comprising the administration of immune modulatory nucleic acids having one or more immune modulatory sequences (IMSs). The invention further relates to the means and methods for the identification of the IMSs for preventing or treating disease, more particularly the treatment and prevention of autoimmune or inflammatory diseases. The invention also relates to the treatment or prevention of disease comprising the administration of the immune modulatory nucleic acids alone or in combination with a polynucleotide encoding self-protein(s), -polypeptide(s) or -peptide(s). The present invention also relates to methods and compositions for treating diseases in a subject associated with one or more self-protein(s), - polypeptide(s) or -peptide(s) that are present in the subject and involved in a non-physiological state.


Patent
Bayhill Therapeutics and Stanford University | Date: 2011-05-18

This invention relates to methods and compositions for treating or preventing disease comprising the administration of immune modulatory nucleic adds having one or more immune modulatory sequences (IMSs). The invention further relates to the means and methods for the identification of the IMSs for preventing or treating disease, more particularly the treatment and prevention of auloimmune or Inflammatory diseases. The invention also relates to the treatment or prevention of disease comprising the administration of the Immune modulatory nucleic acids alone or in combination with a polynucleotide encoding self-proteln(s), -polypeptida(s) or -peptide(s), The present invention also relates to methods and compositions for treating diseases in a subject associated with one or more self-protein(s), - polypeptide(s) or -peptide(s) that are present in the subject and involved In a non-physiological state.


Patent
Bayhill Therapeutics and Stanford University | Date: 2011-06-08

This invention relates to methods and compositions for treating or preventing disease comprising the administration of immune modulatory nucleic acids having one or more immune modulatory sequences (IMSs). The invention further relates to the means and methods for the identification of the IMSs for preventing or treating disease, more particularly the treatment and prevention of autoimmune or inflammatory diseases. The invention also relates to the treatment or prevention of disease comprising the administration of the immune modulatory nucleic acids alone or in combination with a polynucleotide encoding self-protein(s), -polypeptide(s) or -peptide(s). The present invention also relates to methods and compositions for treating diseases in a subject associated with one or more self-protein(s), - polypeptide(s) or -peptide(s) that are present in the subject and involved in a non-physiological state.


Patent
Bayhill Therapeutics and Stanford University | Date: 2011-08-10

This invention relates to methods and compositions for treating or preventing disease comprising the administration of immune modulatory nucleic acids having one or more immune modulatory sequences (IMSs). The invention further relates to the means and methods for the identification of the IMSs for preventing or treating disease, more particularly the treatment and prevention of autoimmune or inflammatory diseases. The invention also relates to the treatment or prevention of disease comprising the administration of the immune modulatory nucleic acids alone or in combination with a polynucleotide encoding self-protein(s), -polypeptide(s) or -peptide(s). The present invention also relates to methods and compositions for treating diseases in a subject associated with one or more self-protein(s), - polypeptide(s) or -peptide(s) that are present in the subject and involved in a non-physiological state.


News Article | December 31, 2008
Site: www.xconomy.com

Bayhill Therapeutics Inc. is focused on the translation of research into therapeutics by developing novel drugs for the treatment of autoimmune diseases.


News Article | January 23, 2009
Site: techcrunch.com

Venture capital firms tightened their purse strings in the fourth quarter of 2008, according to the latest MoneyTree Report released by the National Venture Capital Association and PricewaterhouseCoopers. The total dollar amount invested in venture financings was $5.4 billion, down 33 percent from the fourth quarter of 2007 (when it was $8.09 billion) and down 26 percent from the third quarter of 2008 (when it was $7.3 billion). For the entire year, the total venture capital invested into startups was $28.3 billion, down 8 percent. The decline in investing mapped the decrease in exit options, even though VCs are supposed to have a 5 to 7 year investment horizon. More money continued to flow into later stage deals. And broken down by sector, venture dollars going into Internet deals fell 26 percent quarter over quarter as well to $787 million across 170 deals (a 20 percent decline from the third quarter). Even investments in clean tech startups dipped 14 percent sequentially to $909 million across 62 deals. For the year, Internet financings were pretty much flat at $4.9 billion, while the dollars going into clean tech deals increased 52 percent to $4.1 billion. The ten largest venture fundings in the quarter were: Interactive iCharts and the entire slide deck is embedded below:

Loading Bayhill Therapeutics collaborators
Loading Bayhill Therapeutics collaborators